Incidence, survival time and associated factors of virological failure among adult HIV/AIDS patients on first line antiretroviral therapy in St. Paul's Hospital Millennium Medical College-A retrospective cohort study.

INTRODUCTION: Human Immune deficiency Virus or Acquired Immune deficiency Syndrome (HIV/AIDS) is a pandemic affecting millions around the world. The 2020 the Joint United Nations Programme on HIV/AIDS report stated that the estimated number of people living with HIV (PLHIV) is 38 million globally by 2019. Ethiopia is among HIV high burden countries in Africa. By 2021, PLHIV in Ethiopia is estimated to be 754, 256. Globally out of 25.4 million PLHIV on ART, 41% reported virally non-suppressed. According to UNAIDS, the estimated viral non-suppression in Ethiopia is about 27%.
METHODOLOGY: A hospital based retrospective cohort study was conducted among 323 patients who were enrolled to ART from July 2016 to December 2020. The medical records of study participants were selected using simple random sampling technique & data was collected using data extraction checklist. The collected data was entered and cleaned using SPSS V.25. Kaplan-Meier is used to estimate the cumulative hazard of virological failure at different time points. During bivariate analysis variables with p<0.25 were taken for Multivariate Cox regression analysis to assess predictors of virological failure & statistically significant association was declared at p<0.05 with 95% confidence interval. RESULT: The overall incidence rate of virological failure was 1.75 per 1000 months of observations. The mean survival time of virological failure was 14.80 months. Disclosure of sero-status (AHR = 0.038, 95% CI: 0.008-018), poor adherence (AHR = 4.24, 95% CI: 1.04-16), having OIs (Opportunistic infections) (AHR = 4.59, 95% CI: 1.17-18) and use of cotrimoxazole (CPT) prophylaxis (AHR = 0.13, 95% CI: 0.026-0.68) have shown statistically significant association with virological failure.
CONCLUSION: The incidence of virological failure among patients on first line ART in St. Paul's hospital is low. Disclosure of sero-status, poor adherence, having OIs and use of CPT prophylaxis were associated with virological failure. Therefore, a due attention needs to be given to these factors in order to minimize virological failure in patients on ART.

Introduction

Human Immune deficiency Virus or Acquired Immune Deficiency Syndrome (HIV/AIDS) is a pandemic affecting millions around the world. The 2020 Joint United Nations Programme on HIV/AIDS (UNAIDS) report stated that the estimated number of people living with HIV was 38 million globally by 2019. Despite the efforts to control this pandemic, the infection rate is high; in 2019, the estimated number of new infections was 1.7million. Of 38 million people living with the Human immune deficiency virus, merely 25.4 million are taking antiretroviral therapy while the remaining are waiting. In 2019, HIV/AIDS claimed life of 690,000 people [1]. About a 74.9million people have been infected with HIV since it became a pandemic and 32 million have died of AIDS-related illness [2].

The vast majority of people living with HIV are located in Low- and Middle- Income Countries (LMIC), with an estimated 68% living in sub-Saharan Africa. Among this group, 20.6 million are living in East and Southern Africa where 800,000 new HIV infections were recorded in 2018 [2].

According to an estimate by the ministry of health, the number of PLHIV in Ethiopia by the years 2020 and 2021 will be 745,719 and 754,256 respectively. Antiretroviral drugs are made available in the country for the first time in 2003 and then free in 2005 [3,4]. UNAIDS has reported that only two-thirds of the 690000 people living with HIV in Ethiopia in 2018 are on treatment [5]. Ethiopian Demographic and Health Survey (EDHS) 2016 indicated that the national prevalence of HIV in Ethiopia was 0.96% [6]. The report from Ethiopia Population-based HIV Impact Assessment (EPHIA) indicates that the 2017–2018 prevalence of HIV among adults aged 15–64 years in urban Ethiopia was 3.0%. In Ethiopia, 81% of all people living with HIV are on treatment and 73% of them were virally suppressed which makes the 27% non-suppressed [7].

The prevalence of HIV/AIDS in Addis Ababa, according to EPHIA, 2017–2018 was 3.1% [7]. The ministry of health estimated people living with HIV in Addis Ababa by the years 2020 and 2021 will be 132,524 and 133,720 respectively [3,4]. The HIV care and treatment service coverage in Addis Ababa indicated 74.6% and viral load testing coverage is about 60% with 87.5% viral suppression among those who received viral load testing [8].

HIV has a lifelong treatment, which is monitored by various means. Viral load (VL) testing is among the mechanisms, which gain wider acceptance these days. Measuring VL can help to distinguish between treatment failure and non-adherence. Studies in 2013 WHO recommended viral load testing [9]. WHO defined virological failure (VF) as, plasma viral load above 1000 copies/ ml based on two consecutive viral load measurements after 3 months, with adherence support [10].

As VL testing is becoming routine across countries, measuring its impact and progress towards achieving the UNAIDS target that 90% of people receiving antiretroviral therapy have suppressed viral loads by 2020 (as part of the 90–90–90 targets) is very important [11].

Viral load suppression can be a performance indicator for ART programs. Regular VL-monitoring allows identification of suboptimal adherence. This recommendation is based on research demonstrating that viral suppression is associated with decreased HIV disease progression and mortality among people living with the human immune virus (PLHIV), and the prevention of HIV transmission to sexual partners [12,13].

Virological status follow-up will give initial and precise information on the possibility of treatment failure, the necessity to change regimens, lessen mutations that result from drug resistance, and bring desired outcomes. Therefore, VL tests save patients from being needlessly switched to medicines that are more expensive or left to continue on ineffective therapy that can lead to drug resistance and ultimately death [14,15].

The problem has multidimensional consequences on the individual, family, community, economy, and the health system at large. Virological failure is not a sole entity; it goes hand in hand with drug resistance. VF already endangered the handful of drugs that are in use in a fight against the virus. Even though maintaining a low viral load is important for patients to prevent the progression of AIDS and associated co-infections and the rate of HIV infection in Addis Ababa is high, the evidence on virological failure, survival time and the associated factors are limited. Therefore, this study is aimed to fill this gap in producing evidence that can be useful in making an informed decision. In addition, it will contribute to the realization of the 90-90-90 treatment target and achieve sustainable development goal 3.

Method and materials

A retrospective cohort study was conducted on HIV infected participants on a WHO recommended antiretroviral therapy (ART) and enrolled in Saint Paul’s Hospital Millennium medical college between July 2016 and December 2020.

St. Paul’s Hospital Millennium Medical College is located in Addis Ababa, the capital. The ART service was started in 2003 and currently more than 5080 clients are getting the service free of charge.

Sample size was determined using Epi Info™ Version: 7.2.1.0 StatCalc by considering 95% confidence level, 80% power, unexposed to exposed group ratio of one and taking the key predictor of VF (BMI <16 which gave the largest sample size among the variables) from a previous study in Woldia and Dessie hospitals and Waghimra zone. Therefore, the calculated minimum sample size is 308 and by considering a 10% non-response rate the final sample is 340.

The outcome variable was virological failure is plasma viral load above 1000 copies/ ml based on two consecutive viral load measurements after 3 months, with adherence support. The potential associated factors included age, gender, education, marital status, disclosure status, occupational status, BMI, base line drug regimen, cotrimoxazole prophylaxis, base line functional status, WHO stage, adherence to treatment, TB/HIV co-infection, opportunistic infections other than TB and CD4 cell count. A simple random sampling technique was used to select participants who are greater than 15 years of age and on ART at least for 10 months before data collection. Data was extracted from patient cards using a structured checklist prepared in English adapted from Ethiopian Federal Ministry of Health ART clinic intake and follow up form.

Inclusion and exclusion criteria: The inclusion criteria include: clients aged 15years or older, who were on treatment for at least ten months and on first line ART. Transfer in and those without viral load test were excluded from the study.

Operational definition: Censored are those patients complete the follow up, transferred out or lost without developing virological failure. Adherence is defined as follows: Clients on ART with >95% adherence are considered to have good adherence, those with 85–94% adherence are fair and those with <85% are considered to have poor adherence [16]. History of Opportunistic infection or Tuberculosis indicates whether the patient has history of any Opportunistic infection including Tuberculosis. On the other hand, recent infection is whether the person currently has TB or any Opportunistic infection.

Data were entered, cleared and analyzed using SPSS version 25. Descriptive statistics was used to describe demographic, clinical and medication-related characteristics of patients. The Kaplan-Meier method was used to estimate the cumulative incidence of virological failure at different time points. Incidence of virological failure was calculated using Person months (PM) observation. Cox proportional hazards model was used to identify factors significantly associated with virological failure and to control confounding factors. To control the confounders, a multivariable model was developed for a priori confounders including age and sex which are selected based on existing literature. A p- value of less than 0.05 with 95% was used to declare statistical significance.

This study was approved by the SPHMMC Institutional review Board. An official letter of permission was obtained from the Hospital to access the data from the record of patients that is fully anonymized before we accessed them. An informed verbal consent was obtained from the study participants. The obtained information was kept confidential and only be used for research purpose.

Result

Socio-demographic characteristics

From July 2016 to December 2020, 640 adult HIV patients on first-line ART were enrolled in St. Paul’s hospital millennium medical college ART clinic and 340 medical record cards were selected using simple random sampling of which 17 medical record cards were excluded due to missed charts and incomplete data. As a result, a total of 323 patient cards were included in the analysis

The mean age of the patients was 36.86 (SD±9.8) with minimum age of 16 and maximum 70 years. More than half, 188 (58.2%) of the patients were female. One hundred seven (33.1%) attended primary level of education and 123(38.1%) were with secondary education. Half of the participant in this study 163(50.5%) were married and 142(43.7%) were employed. More than 3/4th of the participants disclosed their HIV status at least for one person (Table 1).

Table 1

Base line Socio-demographic characteristics of first line ART clients in St. Paul’s hospital millennium medical college in Addis Ababa, Ethiopia from July 2016 to December 2020 (N = 323).

Variable	Frequency (%)
Age group
under 20	9(2.8)
21–30	92(28.5)
31–40	121(37.5)
41–50	74(22.9)
51 and above	27(8.3)
Gender
female	188(58.2)
male	135(41.8)
Education
No formal education	37(11.5)
Primary	107(33.1)
Secondary	123(38.1)
College and above	56(17.3)
Marital status
Married	163(50.5)
Never married	142(44)
Divorced/widowed	18(5.6)
Disclosure status
Disclosed	252(78)
Not disclosed	57(17.6)
unknown	14(4.3)
Occupational status
employed	141(43.7)
self employed	42(13.0)
unemployed	132(40.9)
Others	8(2.5)

Baseline clinical and anti-retroviral medication-related characteristics

Majority of the participants 202(62.5%) had normal body mass index. Two hundred sixty nine, 269(83.3%) of the total participants were on Efavernez (EFV) based first line ART drug regimen. More than half of the patients, 174(53.9%) took Cotrimoxazole preventive therapy (CPT). Nearly all 320(99.1%) patients in the study could perform their routine activities. More than half of the patients 193(59.8%) had baseline WHO clinical stage I/II and 247(76.5%) had good ART adherence status. On the other hand, 46(14.2) had TB/HIV co-infection and 82(25.4%) experienced OI other than TB. More than one third (36.5%) had a base line CD4 count of less than 200 copies ml and the mean month of developing virological failure was 30(SD±12) with minimum 10.4 and maximum 53.26 months respectively (Table 2).

Table 2

Baseline clinical and antiretroviral medication-related information among adult HIV patients on first-line ART in St. Paul’s hospital millennium medical college in Addis Ababa, Ethiopia from July 2016 to December 2020 (N = 323).

Variable	Frequency (%)
BMI category (Kg/m2)
under18.5	44(13.6)
18.5–24.9	202(62.5)
25–29.9	65(20.1)
30 and above	12(3.7)
Base line drug regimen
Nevirapine based	11(3.4)
Efavirenz based	269(83.3)
DTG based	43(13.3)
Cotrimoxazole prophylaxis*
yes	174(53.9)
no	149(46.1)
Base line functional status
Working	320(99.1)
Ambulatory	3(0.9)
WHO stage
I/II	193(59.8)
III	79(24.5)
IV	51(15.8)
Adherence to treatment
Fair/poor	76(23.5)
Good	247(76.5)
TB/HIV co-infection
yes	46(14.2)
no	277(85.8)
OIs other than TB
yes	82(25.4)
no	241(74.6)
CD4 (cells/mm3)
200 and below	118(36.5)
201–350	75(23.2)
351–500	52(16.1)
501 and above	60(19.7)
Missing**	18(5.6)

*taken cotrimoxazole prophylaxes at any time in the follow up time.

The incidence of virological failure

All the participants of the study were followed for different periods with a total of 9,698.36 person-months (PM) of observations. The first patient developed the event (VF) after 10.4 months of follow up and the last after 53.3 months. Seventeen, 17(5.3%) of patients developed VF during the follow-up period. The overall incidence rate of VF in this follows up was 1.75 events per 1000 PM of observations. The cumulative hazard of VF at 12, 24, 36 and 48 months were 1.2%, 3.7%, 5.5% and 7.6% respectively.

A graph of the Kaplan Meier (KM) failure function was used to describe the cumulative IR of virological failure over the follow-up period (Fig 1).

Fig 1

Cumulative incidence of VF among first line adult ART patients in St. Paul’s hospital millennium medical college from July 2016 to December 2020.

Survival time of virological failure

The cumulative probability of surviving or being free from the event of interest, VF at the end of 12, 24, 36 and 48 months was 98.76%, 96.30%, 94.49% and 92.35% respectively (Fig 2). The mean survival time of virological failure was 14.8 months.

Fig 2

Kaplan-Meier’s survival graph of patients on ART in St. Paul’s hospital millennium medical college from July 2016 to December 2020.

Factors associated with virological failure

The risk of developing VF among participants disclosed their HIV status decreased by 96.2% compared to their counterparts (AHR) (AHR = 0.038, 95% CI: 0.008–0.18). Patients with poor treatment adherence were four times more likely to develop VF compared to those with good adherence (AHR = 4.24, 95% CI: 1.04–16). Similarly, patients having history of OIs were at four-fold risk of VF compared to those without OIs (AHR = 4.59, 95% CI: 1.17–18). In addition, patients taking cotrimoxazole prophylaxis are 87% less likely to develop to VF compared to those who are not on the prophylaxis (AHR = 0.13, 95% CI: 0.026–0.68) (Table 3).

Table 3

Factors associated with virological failure among first ART clients in St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia from July 2016 to December 2020.

Variable	Event	Censored	P-value	CHR 95% CI	P-value		AHR 95% CI
Gender
Male	12	123	0.023	3.35(1.18–9.51)	0.73		1.26(0.35–4.59)
Female	5	283		1			1.000
Education status
No formal education	2	35	0.31	0.44(0.09–2.2)	0.79		1.38(0.12–16.55)
Primary	3	104	0.04	0.22(0.05–0.91)	0.16		0.19(0.019–1.89)
Secondary	6	117	0.09	0.37(0.12–1.2)	0.52		0.56(0.09–3.22)
college & above	6	50		1			1.000
Base line functional status
Working	16	304	0.069	0.15(0.020–1.16	0.96		0.92(0.039–21)
Ambulatory	1	2		1			1.000
Marital status
Married	7	156	0.21	0.36(0.07–1.74)	0.75		1.52(0.12–19.6)
Never married	8	134	0.36	0.48(0.1–2.3)	0.68		1.75(0.13–23.85)
Divorced/widowed	2	16		1			1.000
Disclosure status
Disclosed	6	246	0.000	0.11(0.04–0.29)	0.000		0.038(0.008–0.18)
Not disclosed	11	46		1			1
Adherence to treatment
Fair/poor	11	65	0.00	6.3(2.31–17.09)		0.040	4.24(1.06–16.9)
Good	6	241		1			1
WHO stage of participant
WHO stage I/II	2	191	0.000	0.041(0.009–0.185)		0.27	0.29(0.03–2.62)
WHO stage III	3	76	0.004	0.15(0.043–0.55)		0.18	0.29(0.05–1.77)
WHO stage IV	12	39		1			1.000
TB/HIV co-infection
Yes	9	37	0.000	7.23(2.77–18.8)		0.11	3.07(0.76–12.36
No	8	269		1			1.000
OIs other than TB	8	269		1			1.000
Yes	12	70	0.000	6.97(2.45–19.7)		0.029	4.59(1.17–18.07)
No	5	236		1			1.000
Cotrimoxazole prophylaxes (CPT)
Yes	11	163	0.18	0.14(0.53–3.9)		0.015	0.13(0.026–0.68)
No	6	143		1			1
CD4 count
CD4 = <200	14	104	0.051	4.45(0.99–19.9)		0.216	3.56(0.476–26.66)
CD4 201–350	1	74	0.490	0.44(0.040–4.8)		0.88	0.82(0.062–10.82)
CD4 351–500	0	52	0.970	0		0.919	0.000
CD4 > = 501	2	58		1			1.000

Discussion

This study assessed the incidence rate of VF and associated factors among adult HIV/AIDS patients on first- line ART attending St. Paul’s hospital millennium medical college in Addis Ababa, Ethiopia.

The overall incidence rate of VF in this study was 1.75 per 1000 PM of observation (95 CI: 0.024–0.068). This result was lower than a finding of similar study conducted in Amhara referral hospital, which was 4.9 per 1000 PM [16]. The reason for discrepancy may be the high proportion of underweight patients in the Amhara hospital study as compared to the current study that is 32.24% vs 13.6%. Studies illustrated that underweight clients on ART are at more risk of VF [17]. In addition, the study in Amhara region hospital reported that proportion of patients with no formal education and primary education was 51% higher compared to the current study, which was 44%, and studies suggested that patients with lower educational level are at higher risk of developing VF [18]. The socio-cultural difference between the study settings may be another contributing factor for the difference in the findings. Majority of the participants of this study were dwellers of the capital, Addis Ababa, with better access to service and information, which might have a contribution for lower Virological Failure.

A similar study in Adama reported the incidence rate of 2.1 per 1000 PM, which was more or less comparable with the result of current study [19]. This could be the physical proximity between the two cities and socio-cultural similarities.

A study in South Africa indicated 3.8 events per 1000 PM observation which was higher than this study [20]. The cohort in South Africa took patients on treatment for a relatively longer duration compared to this study. As indicated in some studies the increase in treatment duration increases the risk of developing VF. The possible explanation for this includes tolerance developed by the patients against advices by professionals, pill fatigue and/ or mutation of the virus over time [21,22]. The other possible reason that caused the discrepancy could be the large sample size used in the South African study.

The incidence rate reported from Ugandan study was 4.8 per 1000 PM, which was higher than the finding in our study [23]. The residence area of the study participants could be an explanation for the observed difference. More than three fourth (76.8%) of the participants were from rural areas of Uganda as opposed to the current study of which majority of the patients were from the capital. This could be explained by the fact that urban residents have better awareness of the treatment and the risk for VF is lesser. The other possible reason could be that the age of the study participants; where 44.1% of the Ugandan cohort were the below the age of 30 years while the proportion of the same age group in current study was 31.3%. As different articles suggest the young age group is highly vulnerable to VF [19,24,25].

Another similar study from India reported a VF incidence rate of 8.9 event per 1000 PM observation [26]. The cause for variation of the two results was the study in India excluded those patients with higher CD4>350 and WHO stage II and I. Patients with advanced WHO staging and lower CD4 count are at risk of developing VF [14,27,28].

The finding of the current study exhibited that the mean survival time of virological failure was 14.8 months. This could be due to the fact that, when clients start a treatment there might be issues with acceptance of the treatment and intolerance to adverse effects may develop which this in turn affects adherence and subsequent development of virological failure.

The study revealed that participants who disclosed their HIV status were 96.2% less likely to develop virological failure. The possible explanation for this could be that, ART is a lifelong treatment and care that demand the support of others. Those who disclosed their status could get the necessary moral, psychological and material support when they are in need in contrast to their counterparts. Patients who declared their HIV status to their loved ones and friends can freely take their medication in front of family members, even reminded by family members and friends to take drugs on time. This study finding is in line with studies in Zimbabwe [29] and Uganda [23].

The other factor found to be significantly associated with VF is poor adherence. Patients with poor adherence are more than 4 times at risk of virological failure than those with good adherences. This finding is in agreement with studies in India [26], Addis Ababa [8] Mekele [14], Gondar [21], Dessie and Woldia [27], Adama [19] and Amhara regional hospitals [16]. In fight against infections like HIV, adhering to the treatment is a key, otherwise it creates a situation that leads to development of resistant varieties that cannot be controlled by the medications at hand. Patients with poor adherence are exposed to CD4 cell reduction, which in turn affects their immune status, and rise viral load [20].

Similarly, the hazard of VF of patients with OIs is 4 times as compared to patients without OIs. Some studies indicate that the presence of other infections with HIV could affect the ART care service [30,31]. Unfortunately, OIs are common among HIV patients. Some OIs are recurrent in nature and made the patient take multiple drugs, this in turn made patient to focus on current illness and give less attention to the chronic condition and pill fatigue may occur. When patient overwhelmed by pill burden they fail to take their ART properly leading to VF [32].

Patients on CPT prophylaxis were 86.6% less likely to develop VF compared to those who did not take the prophylaxis. This happens because CPT increases the CD4 cells of patients and improves their immune status. When the immune system of the patients improve the viral multiplication decreases making them at lower risk of VF [16].

Limitations of this study were, use of secondary data, socio-economic factors like income, behavioral factors like alcohol consumption, smoking and drug use and psychological factors like depression were not included. In addition, though multivariable analyses were adjusted for a known confounder, residual confounding factors cannot be ruled out and the results should be interpreted with caution.

Conclusion

The incidence rate of virological failure was low among HIV patients on the first line ART at St. Paul’s hospital millennium medical college. Higher level of virological failure is observed at early stage of the treatment. The mean survival time of virological failure was 14.8 months. Poor adherence to treatment, failure to disclose HIV status, having OIs and not using cotrimoxazole prophylaxis were the factors associated with increased risk of virological failure. Due attention needs to be given for patients with this conditions during the follow up time.

(SAV)

Click here for additional data file.

24 Nov 2021

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Giordano Madeddu

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide

4. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

- https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0196259

The text that needs to be addressed involves the Introduction.

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study is a retrospective cohort analytic study of virological failure among HIV adult patients on first-line drug treatment and its factor relation in St. Paul's Hospital Millennium Medical College, Ethiopia. These are the comments on this manuscript.

Major comment

1. The result of this study was not a novel finding. Many studies from Ethiopia and in extensive Africa cohort studies explored the several impact factors associated with virological failure (VF), which should add in reference.

2. The methodology was not clear and could not follow by the STROBE checklist. For example: how to study size determined, how the loss to follow-up handled, how and when should be the censor, and how many numbers of completely follow up were analyzed.

3. In table 3, How to report the number of outcome events or summary measures over time.

4. The study duration was July 2016-Dec 2019, but the patient who last developed the event was 53 months, and VF reported at the end of 48 months that were not consistent with the duration of the study.

5. Statistical method was not precise which confounders were chosen to adjust for and why or exploratory multivariate survival was analyzed.

6. Reference 20 could not be comparable in contextualized higher incidence because that previous study was done in naive patients with poor CD4 and high viral load.

7. This manuscript is needed to clarify many points such as good adherence definition, OI/TB former history, or recent infection.

8. In conclusion, Cotrimoxazole prophylaxes(CPT) are given or not depend on the CD4 level. CTP plus antiretroviral (ARV) drug could decrease viral load in cases of an initial high viral load. This study should examine subgroups and interactions among CPT, CD4 level, and ARV.

9. The manuscript's title declared patient used the first-line drug, but the inclusion criteria had not inferred the antiretroviral type. The manuscript should be more clear.

10. Some typo errors and English language in the discussion part might be made readers confused. This study should examine subgroups and interactions among CPT, CD4 level, and ARV.

9. The manuscript's title declared that the patient used the first-line drug but did not infer the antiretroviral type in the inclusion criteria. The manuscript should be more precise.

10. Some typo errors and English language in the discussion part might be made readers confused.

Reviewer #2: PEER REVIEW

Title – Incidence, survival time and associated factors of virological failure among adult HIV/AIDS patients on first line antiretroviral therapy in St. Paul’s Hospital Millennium Medical College - a retrospective cohort study

Authors - Demeke Eshetu Andarge, Haimanot Ewnetu Hailu, Takele Menna

1.0 Summary of the Research and Overall Impression

The research paper by Demeke et al is a retrospective cohort study that was conducted at the St. Paul’s Hospital Millennium Medical College between 2016 to 2019. The study examines 323 HIV/AIDS adult patients on first line antiretroviral (ART) patients enrolled on ART for virological failure. Data was collected using random sampling from medical records. Virological failure was defined as plasma viral load above 1000 copies/ ml based on two consecutive viral load measurements after 3 months, with adherence support. Data on treatment and preventive therapy, CD4 cell count, adherence, coinfection (Opportunistic Infections (OI) and Tuberculosis (TB), body mass index, age, sex, marital status, education level and employment. In addition, patients were categorized based on WHO clinical stage I/II. Analysis was done using Multivariate Cox regression analysis to assess predictors of virological failure and statistically significant at p < 0.05 with 95% confidence intervals were reported. Kaplan–Meier was used to estimate virological failure. The overall incidence rate of VF was 1.75 events per 1000 PM of observations. The mean survival time of virological failure was 14.8 months. Factors associated with virological failure were poor adherence, non-disclosure of HIV status, no prophylaxis use, and OI. More females (58.2%) had viral failure then men, there were slightly more patients with secondary education 38.1% as opposed to primary level of education. Employment and marital status were equally distributed among patients. More than 75% of patients disclosed their status and the mean age for failure was 36.86.

Overall, this paper contributes important information that supports the existing literature on this topic. All relevant data is provided, and the statistical analysis is appropriate.

The research paper provides evidence on Incidence and survival time for virological failure among adult HIV/AIDS on first line antiretroviral therapy. This research is timely, as it provides information that will assist with the determination of the associated factors of virological failure among adult HIV/AIDS patients on antiretroviral therapy in St. Paul’s Hospital Millennium Medical College. The information has implication for the last 90 of the 2020 UNAIDs 9-90-90 target (90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained treatment, and 90% of all people receiving treatment will have viral load suppression). The evaluation of impact of treatment strategy on viral load and disease stage by gender, age, marital status, education level and employment provide important information that can be used to identify areas for intervention during follow up to improve outcome.

It was noted that in the document the author states that the use of CPT prophylaxis was associated with virological failure. The statement in the Results section, Paragraph 5, Factors Associated with Virological Failure, Line 6 “patients taking cotrimoxazole prophylaxis are 87% less likely to develop to VF compared to those who are on the prophylaxis” this statement was not clear. The authors should clarify to avoid confusion and ensure that this statement on results support the conclusion.

2.0 Discussion of specific areas for improvement

Evidence and Examples

Major Issues - There are no major issues to be addressed

Minor Issues -The authors should clarify the following section to avoid confusion

Results- Paragraph 5 - Factors associated with virological failure- Line 6

1. “patients taking cotrimoxazole prophylaxis are 87% less likely to develop to VF compared to those who are on the prophylaxis”

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

4 Jan 2022

We would like to thank the reviewers for their unreserved support. All the comments has been addressed accordingly.

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

13 Jul 2022

Thank you for revising your manuscript to respond to the reviewer's comments. One of the previous reviewers has reviewed the manuscript and considers it suitable for publication, pending a small number of changes that you will see below. The other reviewer was not able to asses your submission, so I have reviewed the response to their comments myself. I have also assessed the manuscript. The following modifications are required for publication:

1) The study dates in the main body of the manuscript were previously updated, but have not been updated in the Abstract - please revise accordingly.

3) Related to the above, please ensure that all variables reported in the Results section are specified in the Methods section and provide details of how each variable was measured.

Please submit your revised manuscript by Aug 26 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

George Vousden

Deputy Editor in Chief

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: PEER REVIEW

Title – Incidence, survival time and associated factors of virological failure among adult HIV/AIDS patients on first line antiretroviral therapy in St. Paul’s Hospital Millennium Medical College - a retrospective cohort study

Authors - Demeke Eshetu Andarge, Haimanot Ewnetu Hailu, Takele Menna

1.0 Summary of the Research and Overall Impression

The research paper by Demeke et al is a retrospective cohort study that was conducted at the St. Paul’s Hospital Millennium Medical College between 2016 to 2019. The study examines 323 HIV/AIDS adult patients on first line antiretroviral (ART) patients enrolled on ART for virological failure. Data was collected using random sampling from medical records. Virological failure was defined as plasma viral load above 1000 copies/ ml based on two consecutive viral load measurements after 3 months, with adherence support. Data on treatment and preventive therapy, CD4 cell count, adherence, coinfection (Opportunistic Infections (OI) and Tuberculosis (TB), body mass index, age, sex, marital status, education level and employment. In addition, patients were categorized based on WHO clinical stage I/II. Analysis was done using Multivariate Cox regression analysis to assess predictors of virological failure and statistically significant at p < 0.05 with 95% confidence intervals were reported. Kaplan–Meier was used to estimate virological failure. The overall incidence rate of VF was 1.75 events per 1000 PM of observations. The mean survival time of virological failure was 14.8 months. Factors associated with virological failure were poor adherence, non-disclosure of HIV status, no prophylaxis use, and OI. More females (58.2%) had viral failure then men, there were slightly more patients with secondary education 38.1% as opposed to primary level of education. Employment and marital status were equally distributed among patients. More than 75% of patients disclosed their status and the mean age for failure was 36.86.

Overall, this paper contributes important information that supports the existing literature on this topic. All relevant data is provided, and the statistical analysis is appropriate.

The research paper provides evidence on Incidence and survival time for virological failure among adult HIV/AIDS on first line antiretroviral therapy. This research is timely, as it provides information that will assist with the determination of the associated factors of virological failure among adult HIV/AIDS patients on antiretroviral therapy in St. Paul’s Hospital Millennium Medical College. The information has implication for the last 90 of the 2020 UNAIDs 9-90-90 target (90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained treatment, and 90% of all people receiving treatment will have viral load suppression). The evaluation of impact of treatment strategy on viral load and disease stage by gender, age, marital status, education level and employment provide important information that can be used to identify areas for intervention during follow up to improve outcome.

It was noted that in the document the author states that the use of CPT prophylaxis was associated with virological failure. The statement in the Results section, Paragraph 5, Factors Associated with Virological Failure, Line 6 “patients taking cotrimoxazole prophylaxis are 87% less likely to develop to VF compared to those who are on the prophylaxis” the statement is contradictory. The authors should clarify to avoid confusion and ensure that the statement of results support the conclusions.

2.0 Discussion of specific areas for improvement

Evidence and Examples

Major Issues

There are no major issues to be addressed

Minor Issues

The authors should clarify the following sections to avoid confusion

Results- Paragraph 5 - Factors associated with virological failure- Line 6

1. “patients taking cotrimoxazole prophylaxis are 87% less likely to develop to VF compared to those who are on the prophylaxis”

Response to Review - April 4, 2022

Response: Thank you for your comment. It is well addressed. It is typo error. It was corrected as follows: Patients taking cotrimoxazole prophylaxis are 87% less likely to develop to VF compared to those who are NOT on the prophylaxis (AHR=0.13, 95% CI: 0.026- 0.68).

Correction noted and accepted in the research paper.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.